Table 1 Demographic and clinical characteristics
Male gender, n (%) | 48 (58) |
|---|---|
Age group, n (%) | |
16–25 years | 2 (2) |
26–35 years | 7 (8) |
36–45 years | 7 (8) |
46–55 years | 17 (20) |
56–65 years | 23 (28) |
66–75 years | 21 (25) |
76 years or older | 6 (7) |
Ethnicity, n (%) | |
American Indian or Alaskan Native | 1 (1) |
Asian | 4 (5) |
Black or African American | 2 (2) |
Hispanic | 4 (5) |
White/Caucasian | 70 (84) |
Native Hawaiian or other Pacific Islander | 1 (1) |
Māori | 1 (1) |
Gout disease duration, n (%) | |
Less than 6 months | 22 (27) |
6 months to 1 year | 10 (12) |
1–5 years | 22 (27) |
6–10 years | 13 (16) |
11–15 years | 5 (6) |
More than 15 years | 11 (13) |
Number of gout flares in past 3 months, n (%) | |
None | 16 (19) |
1–2 | 47 (57) |
3 or more | 20 (24) |
Gout affecting the feet, n (%) | 77 (93) |
Tophi affecting the feet, n (%) | 29 (35) |
Location of gout flares in the feet, n (%) | |
Big toe joint | 59 (73) |
Big toe | 20 (25) |
Lesser toes | 18 (22) |
Midfoot | 21 (26) |
Ankle | 26 (32) |
Heel | 8 (10) |
Other | 10 (12) |
Current foot pain, n (%) | 73 (88) |
Gout medications, n (%) | |
Non-steroidal anti-inflammatory drugs | 27 (33) |
Corticosteroids | 9 (11) |
Colchicine | 24 (29) |
Allopurinol | 34 (41) |
Febuxostat | 5 (6) |
No medication | 8 (10) |